Clinical Trial Update: Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial comparing rituximab to cyclophosphamide in connective tissue disease–associated interstitial lung disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Inflammatory Myositis
• Interstitial Lung Disease
• Mixed Connective Tissue Disease
• Scleroderma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Rituximab (rituximab)

Snippet

Sponsor: Royal Brompton & Harefield NHS Foundation Trust | Conditions: Interstitial Lung Disease, Scleroderma | Phase 2, Phase 3 | Status: COMPLETED